Literature DB >> 19539582

Modified vaccinia Ankara strains with identical coding sequences actually represent complex mixtures of viruses that determine the biological properties of each strain.

Mark Suter1, Christine Meisinger-Henschel, Maria Tzatzaris, Vanessa Hülsemann, Susanne Lukassen, Niels Holger Wulff, Jürgen Hausmann, Paul Howley, Paul Chaplin.   

Abstract

Modified vaccinia Ankara (MVA) was developed by serial passages on chicken embryo fibroblast cells. After passage 570, the virus was considered homogenous and genetically stable. Three MVA strains (MVA-572, MVA-I721 and MVA-BN) have been analyzed and shown to be 100% genetically identical; although significant differences in their phenotypes were illustrated. All MVA strains except MVA-BN replicated in human cells, or killed immune suppressed mice. Viruses isolated from dead animals were shown to represent variants present within MVA-572 or MVA-I721 used to inoculate the mice. These subpopulations were shown to encode mutations, or contain less than the six deletions associated with MVA and had significantly altered phenotypes compared to the parental MVA strains. MVA is a complex polyclonal mixture of viruses, the composition of which governs the phenotype.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19539582     DOI: 10.1016/j.vaccine.2009.05.095

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  29 in total

1.  Immediate-early expression of a recombinant antigen by modified vaccinia virus ankara breaks the immunodominance of strong vector-specific B8R antigen in acute and memory CD8 T-cell responses.

Authors:  Karen Baur; Kay Brinkmann; Marc Schweneker; Juliane Pätzold; Christine Meisinger-Henschel; Judith Hermann; Robin Steigerwald; Paul Chaplin; Mark Suter; Jürgen Hausmann
Journal:  J Virol       Date:  2010-06-10       Impact factor: 5.103

2.  Phase II randomized, double-blinded comparison of a single high dose (5×10(8) TCID50) of modified vaccinia Ankara compared to a standard dose (1×10(8) TCID50) in healthy vaccinia-naïve individuals.

Authors:  Sharon E Frey; Patricia L Winokur; Heather Hill; Johannes B Goll; Paul Chaplin; Robert B Belshe
Journal:  Vaccine       Date:  2014-03-06       Impact factor: 3.641

3.  Recombinant Modified Vaccinia Virus Ankara Generating Ebola Virus-Like Particles.

Authors:  Marc Schweneker; Andrea S Laimbacher; Gert Zimmer; Susanne Wagner; Elisabeth M Schraner; Michael Wolferstätter; Marieken Klingenberg; Ulrike Dirmeier; Robin Steigerwald; Henning Lauterbach; Hubertus Hochrein; Paul Chaplin; Mark Suter; Jürgen Hausmann
Journal:  J Virol       Date:  2017-05-12       Impact factor: 5.103

Review 4.  Smallpox vaccines: targets of protective immunity.

Authors:  Bernard Moss
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

5.  Recombinant modified vaccinia virus Ankara generating excess early double-stranded RNA transiently activates protein kinase R and triggers enhanced innate immune responses.

Authors:  Michael Wolferstätter; Marc Schweneker; Michaela Späth; Susanne Lukassen; Marieken Klingenberg; Kay Brinkmann; Ursula Wielert; Henning Lauterbach; Hubertus Hochrein; Paul Chaplin; Mark Suter; Jürgen Hausmann
Journal:  J Virol       Date:  2014-10-08       Impact factor: 5.103

6.  Introduction of the six major genomic deletions of modified vaccinia virus Ankara (MVA) into the parental vaccinia virus is not sufficient to reproduce an MVA-like phenotype in cell culture and in mice.

Authors:  Christine Meisinger-Henschel; Michaela Späth; Susanne Lukassen; Michael Wolferstätter; Heike Kachelriess; Karen Baur; Ulrike Dirmeier; Markus Wagner; Paul Chaplin; Mark Suter; Jürgen Hausmann
Journal:  J Virol       Date:  2010-07-28       Impact factor: 5.103

7.  The vaccinia virus O1 protein is required for sustained activation of extracellular signal-regulated kinase 1/2 and promotes viral virulence.

Authors:  Marc Schweneker; Susanne Lukassen; Michaela Späth; Michael Wolferstätter; Eveline Babel; Kay Brinkmann; Ursula Wielert; Paul Chaplin; Mark Suter; Jürgen Hausmann
Journal:  J Virol       Date:  2011-12-14       Impact factor: 5.103

8.  Safety, immunogenicity, and surrogate markers of clinical efficacy for modified vaccinia Ankara as a smallpox vaccine in HIV-infected subjects.

Authors:  Richard N Greenberg; Edgar Turner Overton; David W Haas; Ian Frank; Mitchell Goldman; Alfred von Krempelhuber; Garth Virgin; Nicole Bädeker; Jens Vollmar; Paul Chaplin
Journal:  J Infect Dis       Date:  2012-12-07       Impact factor: 5.226

Review 9.  Smallpox vaccines for biodefense.

Authors:  Richard B Kennedy; Inna Ovsyannikova; Gregory A Poland
Journal:  Vaccine       Date:  2009-11-05       Impact factor: 3.641

10.  A randomized, double-blind, dose-finding Phase II study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate IMVAMUNE.

Authors:  Alfred von Krempelhuber; Jens Vollmar; Rolf Pokorny; Petra Rapp; Niels Wulff; Barbara Petzold; Amanda Handley; Lyn Mateo; Henriette Siersbol; Herwig Kollaritsch; Paul Chaplin
Journal:  Vaccine       Date:  2009-11-25       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.